STX1B and neoplasm: In vitro cell-based assays revealed that the Stx1B-scFv OKT3 lectibody can simultaneously engage CTLs and Gb3+ tumor cells, redirecting T cell cytotoxicity in a highly selective manner and resulting in nearly complete tumor cell lysis.